



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Calcitonin salmon nasal spray > Printer-friendly PDF

# Calcitonin salmon nasal spray

**Trade Name:**

Miacalcin NS, Sandoz Calcitonin NS, Apo-Calcitonin NS

**Manufacturer/Distributor:**

Novartis Pharmaceuticals

Sandoz Canada

Apotex Inc.

**Classification:**

Bone metabolism regulator

**ATC Class:**

H05BA - calcitonin preparation

**Status:**

discontinued

**Presentation:**

Nasal spray: 200 IU. DIN: 02240775 (Miacalcin)

Nasal spray: 200 IU. DIN: 02261766 (Sandoz Calcitonin NS)

Nasal spray: 200 IU. DIN: 02247585 (Apo-Calcitonin NS)

**Comments:**

The manufacturers of synthetic calcitonin (salmon) nasal sprays (Miacalcin ? Novartis; Sandoz Calcitonin ? Sandoz; Apo-Calcitonin ? Apotex) ceased sale of these products on July 3, 2013. Distribution will be phased out and DINs cancelled on October 1, 2013. "Health Canada has evaluated information on the risk of malignancies from randomised controlled trials in patients with osteoporosis or osteoarthritis receiving calcitonin (salmon) nasal spray or an unlicensed oral calcitonin formulation. Patients treated with calcitonin in these trials had a low but observable increased rate of malignancies compared with patients taking placebo. The increased rates seen with calcitonin compared to placebo varied between 0.7% in studies with the oral formulation to 2.4% in the studies with the nasal formulation. Taking this new safety information and the available efficacy data into account, Health Canada concluded that the risks of calcitonin (salmon) nasal spray outweigh the benefits for the treatment of established post-menopausal osteoporosis."

**Source:**

Healthy Canadians Website: <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34783a-eng.php>

**Keywords:** calcitonin  
drug discontinuation

**Access:**

public

**Back to:**

*Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)*

**Status:**

<Any>

**Search Terms:**

**Apply**

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada</u> (yyyy/mm/dd)
<u>Moroctocog alfa</u>	Xyntha	Hemostatic agent	2009/01/23
<u>Naloxegol</u>	Movantik	Miscellaneous GI drug	2015/08/27
<u>Naltrexone + bupropion</u>	Contrave	Anorexigenic agents	2018/02/13
<u>Naproxen + Esomeprazole</u>	Vimovo	NSAID + PPI	2011/01/14
<u>Nebivolol</u>	Bystolic	Beta-blocker, cardioselective	2013/04
<u>Niraparib</u>	Zejula	Antineoplastic agent	2020/01/09
<u>Norethindrone acetate + ethinyl estradiol</u>	femHRT	estrogen-progesterone combination	2012/10/09
<u>Norgestrel + ethinyl estradiol</u>	Ovral	Oral contraceptive	
<u>Ofatumumab</u>	Arzerra	Antineoplastic agent	2012/03/09
<u>Ofatumumab</u>	Kesimpta	Immunomodulator	2021/04/08
<u>Olmesartan</u>	Olmetec	Antihypertensive agent	2009/02
<u>Olmesartan + hydrochlorothiazide</u>	Olmetec Plus	Antihypertensive agent	2009/02
<u>Olopatadine</u>	Pataday	Anti-allergy agent	2011/04/14
<u>Onasemnogene</u>	Zolgensma	Cellular and gene therapy	2021/02/04
<u>Ondansetron</u>	Ondissolve ODF	Antiemetic	2013/04
<u>Oxybutynin</u>	Gelnique	Anticholinergic / Antispasmodic	2012/03/05
<u>Oxybutynin</u>	Uromax	Urinary Antispasmodic	

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Oxycodone</u>	OxyContin	Narcotic	2012/02/29
<u>Oxycodone</u>	OxyNEO	Narcotic	2012/01/01
<u>Oxycodone + naloxone</u>	Targin	opioid	2009/12/30
<u>Paliperidone</u>	Invega	Antipsychotic agent	2007/10/02
<u>Paliperidone palmitate</u>	Invega Sustenna	Antipsychotic agent	2010/07/28
<u>Palonosetron</u>	Aloxi	5TH3 antagonist	2012/03/14
<u>Palonosetron + netupitant</u>	Akynzeo	Antiemetic	2017/12/04
<u>Pancrelipase</u>	Cotazym ECS 4 & Cotazym 65B	Pancreatic enzymes	2012/02/06
<u>Pasireotide</u>	Signifor	Synthetic analogue of somatostatin	2013/11/26
<u>Patiromer</u>	Veltassa	Potassium binder	2020/03/09
<u>Pazopanib</u>	Votrient	Antineoplastic agent	2011/08/25
<u>Perampanel</u>	Fycompa	Anticonvulsant	2013/09/04
<u>Pertuzumab</u>	Perjeta	Antineoplastic agent	2013/04/23
<u>Phosphate Effervescent</u>	Phosphate Sandoz		2017/01/01
<u>Pirfenidone</u>	Esbriet	Anti-fibrotic agent	2013/01
<u>Plerixafor</u>	Mozobil	Hematopoietic agent	2012/01/26
<u>Pneumococcal 13-valent conjugate vaccine</u>	Prevnar 13	Vaccine	2010/03/17
<u>Polidocanol</u>	Varithena	Sclerosing agent	2015/08/04
<u>Polyethylene glycol 3350</u>	Lax-a-day	Laxative	2009/03/09

« first [previous](#)    ? [4](#) [5](#) [6](#) [7](#)    **8** [9](#) [10](#) [11](#) [12](#) [next](#) ? [last](#) »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?l?íw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

#### **Terms and Conditions**

---

**Source URL (retrieved on 2025-08-02 03:15):** <http://www.dpic.org/druglisting/calcitonin-salmon-nasal-spray>